ATHIRA PHARMA INC (ATHA) Stock Fundamental Analysis
NASDAQ:ATHA - Nasdaq - US04746L1044 - Common Stock - Currency: USD
Overall ATHA gets a fundamental rating of 2 out of 10. We evaluated ATHA against 195 industry peers in the Pharmaceuticals industry. While ATHA seems to be doing ok healthwise, there are quite some concerns on its profitability. ATHA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
ATHA had negative earnings in the past year.
ATHA had a negative operating cash flow in the past year.
ATHA had negative earnings in each of the past 5 years.
ATHA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -183.27%, ATHA is not doing good in the industry: 90.77% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -213.62%, ATHA is doing worse than 70.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -183.27% | ||
| ROE | -213.62% | ||
| ROIC | N/A |
ROA(3y)-91.8%
ROA(5y)-59.81%
ROE(3y)-115.75%
ROE(5y)-74.32%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ATHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ATHA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ATHA has more shares outstanding
There is no outstanding debt for ATHA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -17.23, we must say that ATHA is in the distress zone and has some risk of bankruptcy.
ATHA's Altman-Z score of -17.23 is on the low side compared to the rest of the industry. ATHA is outperformed by 78.97% of its industry peers.
ATHA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.23 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 7.26 indicates that ATHA has no problem at all paying its short term obligations.
With a decent Current ratio value of 7.26, ATHA is doing good in the industry, outperforming 77.95% of the companies in the same industry.
A Quick Ratio of 7.26 indicates that ATHA has no problem at all paying its short term obligations.
ATHA has a Quick ratio of 7.26. This is in the better half of the industry: ATHA outperforms 78.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.26 | ||
| Quick Ratio | 7.26 |
3. Growth
3.1 Past
ATHA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.13%, which is quite impressive.
EPS 1Y (TTM)32.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
ATHA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.10% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y69.96%
EPS Next 2Y25.41%
EPS Next 3Y19.1%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ATHA. In the last year negative earnings were reported.
Also next year ATHA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ATHA's earnings are expected to grow with 19.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.41%
EPS Next 3Y19.1%
5. Dividend
5.1 Amount
No dividends for ATHA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ATHA (6/16/2025, 11:38:11 AM)
0.3109
+0.01 (+2.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners30.36%
Inst Owner Change-2.09%
Ins Owners2.84%
Ins Owner Change7.95%
Market Cap12.14M
Analysts47.5
Price Target0.41 (31.88%)
Short Float %2.48%
Short Ratio2.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.64%
Min EPS beat(2)6.05%
Max EPS beat(2)13.23%
EPS beat(4)3
Avg EPS beat(4)5.51%
Min EPS beat(4)-4.12%
Max EPS beat(4)13.23%
EPS beat(8)6
Avg EPS beat(8)7.69%
EPS beat(12)9
Avg EPS beat(12)7.28%
EPS beat(16)12
Avg EPS beat(16)7.18%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-27.27%
PT rev (3m)-27.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.88%
EPS NY rev (1m)0%
EPS NY rev (3m)61.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.33 | ||
| P/tB | 0.33 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.07
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-2.2
FCFYN/A
OCF(TTM)-2.2
OCFYN/A
SpS0
BVpS0.96
TBVpS0.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -183.27% | ||
| ROE | -213.62% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-91.8%
ROA(5y)-59.81%
ROE(3y)-115.75%
ROE(5y)-74.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.26 | ||
| Quick Ratio | 7.26 | ||
| Altman-Z | -17.23 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)56.3%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y69.96%
EPS Next 2Y25.41%
EPS Next 3Y19.1%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y37.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.8%
OCF growth 3YN/A
OCF growth 5YN/A